View : 16 Download: 2

Prognostic impact of IPSS-R and chromosomal translocations in 751 Korean patients with primary myelodysplastic syndrome

Title
Prognostic impact of IPSS-R and chromosomal translocations in 751 Korean patients with primary myelodysplastic syndrome
Authors
Suh K.J.Cheong J.-W.Kim I.Kim H.-J.Shin D.-Y.Koh Y.Yoon S.-S.Min Y.H.Ahn J.-S.Kim Y.-K.Lee Y.-G.Lee J.-O.Bang S.-M.Mun Y.-C.Seong C.-M.Park Y.Kim B.-S.Hong J.Park J.Lee J.H.Kim S.-Y.Lee H.G.
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2016
Journal Title
PLoS ONE
ISSN
1932-6203JCR Link
Citation
vol. 11, no. 11
Publisher
Public Library of Science
Indexed
SCIE; SCOPUS WOS scopus
Abstract
Chromosomal translocations are rare in myelodysplastic syndrome (MDS) and their impact on overall survival (OS) and response to hypomethylating agents (HMA) is unknown. The prognostic impact of the revised International Prognostic Scoring System (IPSS-R) and for chromosomal translocations was assessed in 751 patients from the Korea MDS Registry. IPSS-R effectively discriminated patients according to leukaemia evolution risk and OS. We identified 40 patients (5.3%) carrying translocations, 30 (75%) of whom also fulfilled complex karyotype criteria. Translocation presence was associated with a shorter OS (median, 12.0 versus 79.7 months, P < 0.01). Multivariate analysis demonstrated that translocations (hazard ratio [HR] 1.64 [1.06-2.63]; P = 0.03) as well as age, sex, IPSS-R, and CK were independent predictors of OS. In the IPSS-R high and very high risk subgroup (n = 260), translocations remained independently associated with OS (HR 1.68 [1.06-2.69], P = 0.03) whereas HMA treatment was not associated with improved survival (median OS, 20.9 versus 21.2 months, P = 0.43). However, translocation carriers exhibited enhanced survival following HMA treatment (median 2.1 versus 12.4 months, P = 0.03). Our data suggest that chromosomal translocation is an independent predictor of adverse outcome and has an additional prognostic value in discriminating patients with MDS having higher risk IPSS-R who could benefit from HMA treatment. © 2016 Suh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
DOI
10.1371/journal.pone.0166245
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome.PDF(2.16 MB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE